67,408 results match your criteria Myeloma

Cellular Antioxidant Mechanisms Control Immunoglobulin Light Chain-Mediated Proximal Tubule Injury.

Free Radic Biol Med 2021 May 11. Epub 2021 May 11.

Division of Nephrology, Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, 35294-0007; Department of Cell, Developmental and Integrative Biology, University of Alabama at Birmingham, Birmingham, AL, 35294-0007; Department of Veterans Affairs Medical Center, Birmingham, AL, 35233. Electronic address:

A major cause of morbidity and mortality in multiple myeloma is kidney injury from overproduction of monoclonal immunoglobulin light chains (FLC). FLC can induce damage through the production of hydrogen peroxide, which activates pro-inflammatory and pro-apoptotic pathways. The present study focused on catalase, a highly conserved antioxidant enzyme that degrades hydrogen peroxide. Read More

View Article and Full-Text PDF

Pesticide Use and Kidney Function Among Farmers in the Biomarkers of Exposure and Effect in Agriculture Study.

Environ Res 2021 May 11:111276. Epub 2021 May 11.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD. Electronic address:

Background: Pesticides have been reported to be associated with malignant and non-malignant kidney disease. Few studies have examined the relationship between individual pesticides and kidney dysfunction.

Objective: We evaluated the associations of pesticide use with measured kidney function among male pesticide applicators in the Biomarkers of Exposure and Effect in Agriculture (BEEA) study, a subcohort in the Agricultural Health Study. Read More

View Article and Full-Text PDF

CAR T-Cell Therapy in Hematologic Malignancies: Clinical Role, Toxicity, and Unanswered Questions.

Am Soc Clin Oncol Educ Book 2021 Mar;41:1-20

Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.

At the time of writing, five anti-CD19 CAR T-cell products are approved by the U.S. Food and Drug Administration for seven different indications in lymphoid malignancies, including B-cell non-Hodgkin lymphoma, pediatric B-cell acute lymphoblastic leukemia, and multiple myeloma. Read More

View Article and Full-Text PDF

Extramedullary multiple myeloma patient derived orthotopic xenograft with high disturbed genome: combined exhaustive molecular and therapeutic studies.

Dis Model Mech 2021 May 14. Epub 2021 May 14.

Department of Clinical Hematology, Catalan Institute of Oncology, Bellvitge Biomedical Research Institute, Universitat de Barcelona, L'Hospitalet del Llobregat Barcelona, Spain.

Extramedullary multiple myeloma (EMM) has an overall survival of 6 months and occurs in 20% of multiple myeloma (MM) patients. Genetic and epigenetic mechanisms involved in EMM and the therapeutic role of new agents for MM are not well established. Besides, well characterized preclinical models for EMM are not available. Read More

View Article and Full-Text PDF

Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma.

Acta Biomed 2021 May 12;92(2):e2021205. Epub 2021 May 12.

Hematology and Bone Marrow Transplantation Unit - AOUC Policlinico, Department of Emergency and Organ Transplantation, "Aldo Moro" University, 70124, Bari, Italy.

View Article and Full-Text PDF

Low dose venetoclax in combination with bortezomib, daratumumab, and dexamethasone for the treatment of relapsed/refractory multiple myeloma patients-a single-center retrospective study.

Ann Hematol 2021 May 14. Epub 2021 May 14.

James R. Berenson, MD, Inc, West Hollywood, CA, 90069, USA.

Venetoclax is a BCL-2 inhibitor currently indicated for use in treating hematologic malignancies with recommended doses ranging from 400 to 600 mg/day. Although currently not FDA-approved to treat multiple myeloma (MM) patients, there is a growing number of reports indicating its efficacy as a salvage therapy for these patients, especially for those with the t(11;14) chromosomal marker. These studies, however, have also indicated that venetoclax given at doses ≥ 400 mg/day can cause serious adverse events (SAEs) especially when administered with bortezomib, commonly related to infections. Read More

View Article and Full-Text PDF

Propelling Healthcare with Advanced Therapy Medicinal Products: A Policy Discussion.

Biomed Hub 2020 Sep-Dec;5(3):130-152. Epub 2020 Dec 3.

Institute of Molecular and Translational Therapeutic Strategies (IMTTS), Hannover Medical School, Hannover, Germany.

Recent advances in biomedicine are opening the door to new approaches, and treatment and prevention are being transformed by novel medicines based on genetic engineering, innovative cell-based therapies and tissue-engineered products, and combinations of a medical device with embedded cell or tissue components. These advanced therapy medicinal products (ATMPs) hold one of the keys to making a reality of genuinely personalised medicine. There are an estimated 450 companies across the globe working on the development of gene therapies and more than 1,000 clinical trials underway worldwide, and some 20-30 new ATMPs filings are expected in Europe annually over the next 5 years. Read More

View Article and Full-Text PDF
December 2020

Lenalidomide-Associated Hemophagocytic Lymphohistiocytosis With Plasma Cell Phagocytosis.

Cureus 2021 Apr 10;13(4):e14409. Epub 2021 Apr 10.

Hematology and Oncology, Brooke Army Medical Center, San Antonio, USA.

Hemophagocytic lymphohistiocytosis (HLH) is a severe systemic inflammatory syndrome that is often fatal. In the adult population, it is believed to develop secondary to immune dysregulation due to rheumatologic, infectious, malignant, and recently, immunomodulatory drugs. It's co-occurrence with phagocytosis by non-macrophage cells has not been previously well defined. Read More

View Article and Full-Text PDF

Severe Right-Sided Heart Failure and Pulmonary Hypertension with Carfilzomib Treatment in Multiple Myeloma.

Heart Views 2020 Oct-Dec;21(4):296-299. Epub 2021 Jan 14.

Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, AR, USA.

Carfilzomib, a second-generation irreversible proteasome inhibitor, is currently considered the preferred therapy for relapsed and refractory multiple myeloma. There are several cardiovascular adverse effects described with carfilzomib chemotherapy most commonly being hypertension, dyspnea and decreased cardiac ejection fraction. We report a case of newonset pulmonary hypertension with right ventricular (RV) heart failure in a patient receiving carfilzomib. Read More

View Article and Full-Text PDF
January 2021

Progression to Symptomatic Multiple Myeloma Predicted by Texture Analysis-Derived Parameters in Patients Without Focal Disease at F-FDG PET/CT.

Clin Lymphoma Myeloma Leuk 2021 Apr 6. Epub 2021 Apr 6.

Dipartimento di Scienze Radiologiche ed Ematologiche, Istituto di Medicina Nucleare, Università Cattolica del Sacro Cuore, Rome, Italy; Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, UOC di Medicina Nucleare, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.

This retrospective study is focused on the possible clinical implications of texture analysis-derived PET parameters in patients with smoldering multiple myeloma. Several texture features are significantly associated with progression to symptomatic multiple myeloma and with a shorter time to progression. The results of this study may lead to early identification of patients who could benefit from specific therapies. Read More

View Article and Full-Text PDF

KD-PACE Salvage Therapy for Aggressive Relapsed Refractory Multiple Myeloma, Plasma Cell Leukemia and Extramedullary Myeloma.

Clin Lymphoma Myeloma Leuk 2021 Apr 6. Epub 2021 Apr 6.

Department of Medicine, Division of Hematology and Oncology, Vanderbilt University Medical Center, Nashville, TN, USA.

Background: Patients with advanced/aggressive multiple myeloma have limited treatment options to achieve rapid disease control. In eligible patients, bortezomib, dexamethasone, thalidomide, cisplatin, doxorubicin, cyclophosphamide, and etoposide is often used. However, many patients are refractory to or have toxicities from bortezomib and there is a need for bridging therapy. Read More

View Article and Full-Text PDF

Selinexor for the treatment of patients with previously treated multiple myeloma.

Expert Rev Hematol 2021 May 14. Epub 2021 May 14.

Jerome Lipper Multiple Myeloma Center, Department of Medical Oncology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, MA, USA.

Introduction: : Multiple myeloma (MM) is an increasingly treatable but still incurable hematologic malignancy. Prognosis has improved significantly over recent years, although further advances remain urgently needed, especially for patients with heavily pre-treated and resistant disease for whom there are limited options. Selinexor is a first-in-class, oral, selective inhibitor of nuclear export (SINE) compound that triggers apoptosis in malignant cells by inducing nuclear retention of oncogene messenger RNAs (mRNAs) and reactivation of tumor suppressor proteins (TSPs). Read More

View Article and Full-Text PDF

Progress in the Management of Smoldering Multiple Myeloma.

Curr Hematol Malig Rep 2021 May 13. Epub 2021 May 13.

University of Wisconsin Carbone Cancer Center, 600 Highland Ave, Madison, WI, 3792, USA.

Purpose Of Review: Smoldering multiple myeloma (SMM) is defined as an asymptomatic clonal proliferation of pre-malignant plasma cells and an increased risk of progression to multiple myeloma (MM) relative to monoclonal gammopathy of undetermined significance. Whether patients with SMM should be treated prior to development of symptomatic disease is fiercely debated and is a highly active area of research.

Recent Findings: The ECOG E3A06 study demonstrated that early treatment with lenalidomide significantly reduced the risk of progression to MM compared to observation in patients with high risk SMM. Read More

View Article and Full-Text PDF

Identification and Validation of a Novel RNA-Binding Protein-Related Gene-Based Prognostic Model for Multiple Myeloma.

Front Genet 2021 26;12:665173. Epub 2021 Apr 26.

Taizhou Hospital of Zhejiang Province Affiliated to Wenzhou Medical University, Linhai, China.

Background: Multiple myeloma (MM) is a malignant hematopoietic disease that is usually incurable. RNA-binding proteins (RBPs) are involved in the development of many tumors, but their prognostic significance has not been systematically described in MM. Here, we developed a prognostic signature based on eight RBP-related genes to distinguish MM cohorts with different prognoses. Read More

View Article and Full-Text PDF

Expanded natural killer cells augment the antimyeloma effect of daratumumab, bortezomib, and dexamethasone in a mouse model.

Cell Mol Immunol 2021 May 12. Epub 2021 May 12.

Research Center for Cancer Immunotherapy, Chonnam National University Hwasun Hospital and Chonnam National University Medical School, Gwangju, Korea.

The use of natural killer (NK) cells is a promising and safe immunotherapeutic approach in the field of cancer immunotherapy. However, combination treatments are required to enhance the effector functions and therapeutic efficacy of NK cells. In this study, we investigated the potential of daratumumab (Dara), bortezomib, and dexamethasone (Dvd) to augment the antitumor effects of NK cells in a multiple myeloma (MM) xenograft mouse model. Read More

View Article and Full-Text PDF

EGR1 addiction in diffuse large B cell lymphoma.

Mol Cancer Res 2021 May 12. Epub 2021 May 12.

Medicine, University of Wisconsin School of Medicine and Public Health

Early growth response gene (EGR1) is a transcription factor known to be a downstream effector of B cell receptor signaling and Janus kinase 1 (JAK1) signaling in diffuse large B cell lymphoma (DLBCL). While EGR1 is characterized as a tumor suppressor in leukemia and multiple myeloma, the role of EGR1 in lymphoma is unknown. Here we demonstrate that EGR1 is a potential oncogene that promotes cell proliferation in DLBCL. Read More

View Article and Full-Text PDF

Accidental Ixazomib Overdose in a Patient With Multiple Myeloma.

J Investig Med High Impact Case Rep 2021 Jan-Dec;9:23247096211013230

SUNY Upstate Medical University, Syracuse, NY, USA.

Multiple myeloma is the second most common hematological malignancy. Ixazomib is the first oral proteasome inhibitor approved in the United States for the management of multiple myeloma who have received at least one prior treatment. The availability of oral chemotherapeutic agents for the management of multiple myeloma has made it easier for patients who do not have to come to the hospital for chemotherapy infusions. Read More

View Article and Full-Text PDF

[Influence of prognostic nutritional index and controlling nutritional status on the prognosis of patients with multiple myeloma].

Zhonghua Xue Ye Xue Za Zhi 2021 Apr;42(4):332-337

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

To explore the influence of prognostic nutritional index (PNI) and controlling nutritional status (CONUT) on the prognosis of patients with multiple myeloma. Data of 157 patients with multiple myeloma (MM) at the affiliated hospital of Xuzhou medical university from January 2014 to December 2018 were retrospectively evaluated. The operating characteristic (ROC) curve analysis was adopted as the optimal cut-off point. Read More

View Article and Full-Text PDF

[Analysis of the clinical characteristics and prognosis of 36 cases of newly diagnosed multiple myeloma patients with bone marrow monoclonal plasma cell ratio of less than 10].

Zhonghua Xue Ye Xue Za Zhi 2021 Apr;42(4):295-301

Peking Union Medical College, Chinese Academy of Medical Sciences & Department of Hematology, Peking Union Medical College Hospital, Beijing 100730, China.

To improve the understanding of newly diagnosed multiple myeloma (NDMM) patients with bone marrow (BM) monoclonal plasma cell ratio of less than 10%. The clinical characteristics, laboratory examination, response to treatment, and prognosis of 36 NDMM patients with BM plasma cell ratio of less than 10% at Peking Union Medical College Hospital from January 2009 to December 2017 were summarized retrospectively. In the same period, other age- and gender-matched 72 NDMM patients were selected as the control group, whose BM plasma cell ratio was equal to or greater than 10%. Read More

View Article and Full-Text PDF

Prediction of High-Risk Cytogenetic Status in Multiple Myeloma Based on Magnetic Resonance Imaging: Utility of Radiomics and Comparison of Machine Learning Methods.

J Magn Reson Imaging 2021 May 12. Epub 2021 May 12.

Department of Radiology, Peking University Third Hospital, Haidian District, Beijing, People's Republic of China.

Background: Radiomics has shown promising results in the diagnosis, efficacy, and prognostic assessments of multiple myeloma (MM). However, little evidence exists on the utility of radiomics in predicting a high-risk cytogenetic (HRC) status in MM.

Purpose: To develop and test a magnetic resonance imaging (MRI)-based radiomics model for predicting an HRC status in MM patients. Read More

View Article and Full-Text PDF

Validity and reliability of the QLQ-MY20 module for assessing the health-related quality of life in Brazilians with multiple myeloma.

Curr Med Res Opin 2021 May 12. Epub 2021 May 12.

Department of Social Pharmacy - UFMG. Belo Horizonte, Minas Gerais, Brazil.

Purpose: Multiple myeloma (MM) is a rare but treatable hematological cancer, which makes Health-Related Quality of Life (HRQoL) an important patient-report outcome measure in clinical studies. The Quality of Life Questionnaire Multiple Myeloma Module (QLQ-MY20) was developed by the European Organization for Research and Treatment of Cancer (EORTC) to measure HRQoL in people with MM. However, the Brazilian Portuguese version of QLQ-MY20 has not yet been validated for Brazil. Read More

View Article and Full-Text PDF

Characterize, Optimize, and Harmonize: Caring for Older Adults With Hematologic Malignancies.

Am Soc Clin Oncol Educ Book 2021 Mar;41:1-9

Department of Hematology and Hematopoietic Cell Transplantation, City of Hope, Duarte, CA.

With the aging of the population, the number of older adults with hematologic malignancies is growing, and treatment paradigms for these patients are rapidly evolving. Use of allogeneic stem cell transplant has been expanding to include septuagenarians but remains a potentially morbid procedure, creating an opportunity for a geriatric-focused evaluation to improve assessment of the individual's risk in undergoing the procedure. Although age alone should not be the sole determinant for transplant eligibility, geriatric assessment often identifies vulnerabilities that are not captured in assessing performance status and comorbidities alone. Read More

View Article and Full-Text PDF

Updates and Ongoing Challenges in Imaging of Multiple Myeloma: Expert Panel Narrative Review.

AJR Am J Roentgenol 2021 May 12. Epub 2021 May 12.

University of Maryland School of Medicine, Baltimore, MD 21201, USA.

Recent advances in the understanding and treatment of multiple myeloma have led to the need for more sensitive and accurate imaging of intramedullary and extramedullary disease. This role of imaging is underscored by recently revised imaging recommendations of the International Myeloma Working Group (IMWG). This narrative review discusses the recent recommendations from the IMWG for different disease stages, focusing on advanced whole-body modalities, and addresses related challenges and controversies. Read More

View Article and Full-Text PDF

Second allogeneic transplants for multiple myeloma: a report from the EBMT Chronic Malignancies Working Party.

Bone Marrow Transplant 2021 May 11. Epub 2021 May 11.

Univ. Lille, CHU Lille, INSERM, Infinite, U1286, Lille, France.

The EBMT Chronic Malignancies Working Party performed a retrospective analysis of 215 patients who underwent a second allo-HCT for myeloma between 1994 and 2017, 159 for relapse and 56 for graft failure. In the relapse group, overall survival (OS) was 38% (30-46%) at 2 years and 25% (17-32%) at 5 years. Patients who had a HLA-identical sibling (HLAid-Sib) donor for their first and second transplants had superior OS (5 year OS: HLAid-Sib/HLAid-Sib: 35% (24-46%); Others 9% (0-17%), p < 0. Read More

View Article and Full-Text PDF

Conditional relative survival among patients with nodular lymphocyte-predominant Hodgkin lymphoma in the Netherlands.

Blood Cancer J 2021 May 11;11(5):87. Epub 2021 May 11.

Amsterdam UMC, Vrije Universiteit Amsterdam, Department of Hematology, Cancer Center Amsterdam, Amsterdam, The Netherlands.

View Article and Full-Text PDF

Feature-weighted Ordinal Classification for Predicting Drug Response in Multiple Myeloma.

Bioinformatics 2021 May 11. Epub 2021 May 11.

Department of Statistics, University of Georgia, Athens, GA 30602, USA.

Motivation: Ordinal classification problems arise in a variety of real-world applications, in which samples need to be classified into categories with a natural ordering. An example of classifying high-dimensional ordinal data is to use gene expressions to predict the ordinal drug response, which has been increasingly studied in pharmacogenetics. Classical ordinal classification methods are typically not able to tackle high-dimensional data and standard high-dimensional classification methods discard the ordering information among the classes. Read More

View Article and Full-Text PDF

Leptomeningeal and intraventricular myelomatosis manifesting an aggressive form of communicating hydrocephalus.

Neuropathology 2021 May 10. Epub 2021 May 10.

Department of Neuropathology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Hirosaki, Japan.

Leptomeningeal myelomatosis (LMM) is a fatal complication that occurs in < 1% of patients with multiple myeloma. Many patients with LMM present with neurologic symptoms referable to cranial neuropathies, while the manifestation of communicating hydrocephalus has been underrecognized. A Japanese man with Bence Jones protein-κ multiple myeloma developed fever and headache at age 54 years. Read More

View Article and Full-Text PDF

Gene expression derived from alternative promoters improves prognostic stratification in multiple myeloma.

Leukemia 2021 May 10. Epub 2021 May 10.

Area de Oncología, Centro de Investigación Médica Aplicada (CIMA), Universidad de Navarra, IDISNA, Pamplona, Spain.

Clinical and genetic risk factors are currently used in multiple myeloma (MM) to stratify patients and to design specific therapies. However, these systems do not capture the heterogeneity of the disease supporting the development of new prognostic factors. In this study, we identified active promoters and alternative active promoters in 6 different B cell subpopulations, including bone-marrow plasma cells, and 32 MM patient samples, using RNA-seq data. Read More

View Article and Full-Text PDF

Discovery of candidate DNA methylation cancer driver genes.

Cancer Discov 2021 May 10. Epub 2021 May 10.

New York Genome Center

Epigenetic alterations such as promoter hypermethylation may drive cancer through tumor suppressor genes inactivation. However, we have limited ability to differentiate driver DNA methylation (DNAme) changes from passenger events. We developed DNAme driver inference - MethSig - accounting for the varying stochastic hypermethylation rate across the genome and between samples. Read More

View Article and Full-Text PDF